BridgeMD
Comparison of the effects of prophylactic administration of Apixaban on thrombin generation in patients with de novo multiple myeloma and patients undergoing a surgery for total knee replacement: the ProApix Study
EU CTIS ID: 2024-515329-27-00
What this study is testing
To compare the pharmacodynamic effect of Apixaban measured by thrombin generation by thrombinography at peak concentration following a 2.5mg dose in patients treated for de novo multiple myeloma (i.e. chemotherapy naïve) (group 1) and in patients operated on for PTG (group 2) in a peripheral venous blood sample taken 2h (32) after Apixaban (H2).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient over 18 years of age.
- Signed informed consent.
- Patient covered by a social security scheme.
- Group 1 (MM): Patient suffering from de novo multiple myeloma for whom treatment including thromboprophylaxis with apixaban is recommended.
- Group 2 (PTG): Patient undergoing knee joint replacement with a total prosthesis for whom thromboprophylaxis with apixaban is recommended.
You likely can't join if
- Indication for curative anticoagulant treatment.
- Contraindication to the use of apixaban.
- Pregnant or breast-feeding woman.
- Refusal to sign the consent form.
- Protected adult patient.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.